Skip to main content
. 2015 Oct 12;6(37):40141–40157. doi: 10.18632/oncotarget.5653

Figure 4. MPN patient erythroid colony formation is inhibited by AZD1208 mono-therapy and synergistically inhibited with AZD1208 and ruxolitinib combination therapy.

Figure 4

A. Peripheral blood mononuclear cells (PBMCs) from two MPN patients were plated in methylcellulose, containing cytokines but lacking erythropoietin (Epo), in the presence of DMSO or SGI-1776 (3 μM). Epo-independent erythroid colonies (EECs) were counted 14 days later. Similarly, cells from two healthy controls (HC) were plated in the same medium containing Epo, and erythroid colonies were determined 14 days later. Data are represented as percent of DMSO samples. B. PBMCs from three MPN patients (left) and two healthy controls (right) were plated, as in A., with the indicated doses of AZD1208. Erthyroid colonies were determined 14 days later and are represented as percent of DMSO samples. C. PBMCs from MPN patients were plated as in A. with DMSO, AZD1208, and ruxolitinib alone or in combination. Drug concentrations used: MPN6–10, 0.2 μM AZD1208 and 0.05 μM ruxolitinib; MPN11–15, 0.1 μM AZD1208 and 0.05 μM ruxolitinib; MPN16, 0.1 μM AZD1208, 0.01 μM ruxolitinib; and MPN17, 0.2 μM AZD1208 and 0.1 μM ruxolitinib. Erythyroid colonies were determined 14 days later and are represented as percent of DMSO samples. Error bars indicate standard deviation. D. Summary of data in C. with mean +/− 95% confidence interval indicated. P value was calculated by paired t-test. All samples were from JAK2-V617F-positive MPN patients: samples MPN1, 6, 7, 8, 12, 13, 15, and 16 were from PV patients; MPN3, 5, 9, 10, 14, and 17 were from ET patients; and MPN2, 4, and 11 were from MF patients.